Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026)
Earth Science Tech's (ETST) quarterly Net Income towards Common Stockholders came in at $1.3 million in Q1 2026, up 9.84% YoY from $1.2 million in Q1 2025, and up 41.48% on a QoQ basis from $910368.0 in Q4 2025.
Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Earth Science Tech (ETST) has 15 years of Net Income towards Common Stockholders data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 9.84% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 10.67% YoY) and the FY2026 annual result came in at $3.6 million, up 10.67% from the prior year.
- Net Income towards Common Stockholders climbed to $1.3 million in Q1 2026, from $910368.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 million in Q1 2026 to a low of -$235509.0 in Q1 2023.
- A 5-year average of $430719.9 and a median of $229324.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 667.61% — and 2024, when it jumped 3123.53%.
- Tracing ETST's Net Income towards Common Stockholders over 5 years: stood at $98464.0 in 2022, then surged by 128.96% to $225443.0 in 2023, then retreated by 8.44% to $206411.0 in 2024, then surged by 341.05% to $910368.0 in 2025, then soared by 41.48% to $1.3 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $1.3 million (Q1 2026), $910368.0 (Q4 2025), and $945897.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Earth Science Tech | 31.63 Mn | 28.84 Mn | 6.28 Mn | 715,697.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 715,697.00 |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 910,368.00 |
| Sep 30, 2025 | 945,897.00 |
| Jun 30, 2025 | 456,714.00 |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 206,411.00 |
| Sep 30, 2024 | 798,368.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 229,324.00 |
| Dec 31, 2023 | 225,443.00 |
| Sep 30, 2023 | 444,581.00 |
| Jun 30, 2023 | -35,596.00 |
| Mar 31, 2023 | -235,509.00 |
| Dec 31, 2022 | 98,464.00 |
| Sep 30, 2022 | -73,678.00 |
| Jun 30, 2022 | -154,682.00 |
| Mar 31, 2022 | -30,681.00 |
| Dec 31, 2021 | -115,048.00 |
| Sep 30, 2021 | 3.34 Mn |